MOBI · Mobia Medical, Inc.
The latest filing states the doubt was alleviated.
“In prior reporting periods, the Company concluded that recurring operating losses, negative cash flows from operations, and future expenditures raised substantial doubt about its ability to continue as a going concern. In May 2026, the Company completed its IPO and received net proceeds of approximately $134.0 million. As a result of the additional liquidity provided by the completed IPO, management concluded that the existing cash and cash equivalents are sufficient to fund its operations and meet its obligations for at least one year from the date these condensed unaudited interim financial statements are issued. Accordingly, management concluded that the conditions and events described above do not raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Price & Indicators
The closing range uses available history since May 8, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 14, 2026TL;DR. Mobia Medical posted Q2 2026 revenue of $13.5 million, up 102% year-over-year, driven by Vivistim system adoption, and is initiating full-year 2026 revenue guidance of $54.0–$56.0 million (69–75% growth) following its IPO that raised approximately $134.0 million in net proceeds.
- + Company is initiating full-year 2026 revenue guidance of $54.0–$56.0 million, implying 69–75% growth.
- + Active territories expanded 92% year-over-year to 35.5 average in Q2, with 367 units sold.
- + IPO completed in May 2026, raising approximately $134.0 million in net proceeds, with $177.1 million cash on the balance sheet to fund commercial expansion.
- + Gross margin expanded to 83.2% in Q2 2026 from 82.3% in Q2 2025.
- − Net loss widened to $21.0 million in Q2 2026 from $10.5 million in Q2 2025.
- − Operating expenses increased 83% to $29.2 million, with SG&A up 85% and R&D up 61%, as commercial headcount and IPO-related costs expanded.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross margin | 83.2% | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MOBI
this stock
Mobia Medical, Inc.
|
$301.62M | — | — | — | 1.4% |
|
ABT
Abbott Laboratories
|
$174.90B | -22.2% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MOBI | +1.3% | -21.1% | — | -2.9% | — |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +1.5% | -20.6% | — | -3.8% | — |